Mycophenolate, tacrolimus and posttransplant lymphoproliferative disorder: A report of the North American Pediatric Renal Transplant Cooperative Study

Pediatric Transplantation

Volumn 6, Issue 5, 2002, Pages 396-399

  Dharnidharka, Vikas R ^a,e   Ho, Ping Leung ^b   Stablein, Donald M ^b   Harmon, William E ^c   Tejani, Amir H ^d  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b EMMES CORPORATION   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

^e Box 10 ^*  (United States)

Author keywords

Mycophenolate; Pediatric kidney transplantation; PTLD; Tacrolimus

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; COMPUTER PROGRAM; DATA BASE; DISEASE ASSOCIATION; DOSE TIME EFFECT RELATION; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEWBORN; REGISTER; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; CHEMICALLY INDUCED DISORDER; IMMUNOLOGY;

FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MULTICENTER STUDIES; MYCOPHENOLIC ACID; TACROLIMUS;

EID: 0036771833     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.2002.00021.x     Document Type: Article

References (13)

1. Nalesnik MA. Clinicopathologic features of posttransplant lymphoproliferative disorders. Ann Transplant 1997: 2: 33-40.
2. Harmon WE, Dharnidharka VR. Lymphoproliferative disease in children. Transplant Proc 1999: 31: 1268-1269.
3. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995: 59: 524-529.
4. Ellis D, Jaffe R, Green M, et al. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. Transplantation 1999: 68: 997-1003.
5. Newell KA, Alonso EM, Whitington PF, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 1996: 62: 370-375.
6. Sokal EM, Antunes H, B C, et al. Early signs and risk factors for the increased incidence of Epstein- Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation 1997: 64: 1438-1442.
7. Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA. Posttransplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center. Transplantation 1993: 56: 88-96.
8. Dharnidharka VR, Sullivan EK, Stablein DM, Tejani AH, Harmon WE. Risk factors for post transplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001: 71: 1065-1068.
9. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990: 323: 1723-1728.
10. Younes BS, McDiarmid SV, Martin MG, et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation 2000: 70: 94-99.
11. Sarmiento JM, Dockrell DH, Schwab TR, Munn SR, Paya CV. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant 2000: 14: 136-138.
12. Alexander SR, Arbus GS, Butt KM, et al. The 1989 report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 1990: 4: 542-553.
13. Penn I. Post-transplant malignancy, the role of immunosuppression. Drug Saf 2000: 23: 101-113.